Picard Medical, Inc.

Picard Medical, Inc. is a U.S.-based medical technology holding company whose operating business is conducted through SynCardia. The company develops, manufactures, and sells the SynCardia Total Artificial Heart, an FDA-approved implantable device used to temporarily replace both ventricles of the heart in patients with advanced heart failure.

−265,1 %

−4,1 %

−546,6 %

+12,5 %

1.11

0.72

— Picard Medical, Inc.
	%
Implantable total artificial heart systems	65% FDA-approved implantable heart replacement devices used as a bridge to transplant.
Driver rentals	20% Rental of external Freedom drivers that power the implanted heart system.
Training and certification services	10% Required training for transplant centers before first-time deployment of the system.
Aftercare and related services	5% Support services for centers and patients using the SynCardia platform.

Customers are specialized transplant centers and hospital programs that treat patients with advanced heart failure and...

U.S. transplant centersprimary
Buy the implantable TAH, driver rentals, and training to treat bridge-to-transplant patients.
International transplant centerssecondary
Use the system under special exemptions or compassionate use for selected patients.
Hospital and clinical programssecondary
Purchase support services and device-related infrastructure to run the therapy.
Patient aftercare programsemerging
Use ongoing support tied to implanted patients and center operations.

The company is headquartered in the United States, where the SynCardia TAH is commercially approved and sold...

•United States is the core commercial market
•Device is FDA-approved for U.S. bridge-to-transplant use
•International use occurs under special exemptions
•Implants have been reported in 27 countries globally
•Foreign access depends on local regulatory pathways

Picard Medical's strategy is centered on SynCardia and the next generation of total artificial heart technology...

Develop next-generation total artificial heart systemsmedium-term

Improves usability, outcomes, and long-term competitiveness of the platform.

Expand the cardiovascular portfoliolong-term

Reduces dependence on a single product and broadens future growth options.

Protect and extend intellectual propertymedium-term

Patent protection supports differentiation and barriers to entry.

The business is highly concentrated in a single commercial product and depends on a narrow set of specialized...

high

Product concentration

Most business activity depends on one FDA-approved heart system.

Scope: SynCardia TAH
Materiality: high

high

Regulatory and reimbursement dependence

Sales depend on approval status, special exemptions, and hospital economics.

Scope: U.S. and international access
Materiality: high

high

Manufacturing and quality risk

Implantable devices require consistent production quality and traceability.

Scope: Device manufacturing
Materiality: high

high

Financing and liquidity risk

The company has relied on external capital to fund operations and growth.

Scope: Operating runway
Materiality: high

medium

Clinical adoption risk

Transplant centers must be trained and willing to deploy a complex device.

Scope: Transplant centers
Materiality: medium

Revenue recognition by product, rental, and services

Affects quarterly comparability and reported revenue mix

Inventory valuation and obsolescence

Affects cost of revenues and gross loss

Embedded derivatives in convertible instruments

Affects earnings volatility

Stock-based compensation and debt discount amortization

Affects operating expenses and financing-related costs

Picard Medical, Inc.

Product concentration

Regulatory and reimbursement dependence

Manufacturing and quality risk

Financing and liquidity risk

Clinical adoption risk

Edwards Lifesciences Corp

Adagio Medical Holdings, Inc.

BioCardia, Inc.

VYCOR MEDICAL INC

STRYKER CORP

IR-Med, Inc.